ClinicalTrials.gg
WithdrawnNCT05572463Updated Nov 18, 2022

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

A Phase 1/2 interventional study of Sintilimab + IBI110 in Unresectable Cutaneous Melanoma and Metastatic Cutaneous Melanoma, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Withdrawn at 13 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-18.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
Sponsor Strategy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,049 studies in Melanoma with a site in United States — 243 open to participants now, 440 under way, 32 of them phase 3. Melanoma · United States.

Enrollment
1,704th of 1,749
0 · median 37
Started
2022
with 87 others
Phase 1/2
287 of 2,049
51 open now
Registered
1,779th of 2,049
by date

Among the 2,049 studies in Melanoma with a site in United States, this one is the 1,704th largest by enrollment of the 1,749 interventional ones that give a count, is one of 88 that started in 2022, is one of 287 in phase 1/2, and was the 1,779th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

243 of the 2,049 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:

238 more — sign in →

All 243 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,049 studies in Melanoma with a site in United States, or all of them as a file.
02

Study summary

This is a platform study evaluating the safety and efficacy of multiple novel investigational products (IPs) that target unresectable or metastatic cutaneous melanoma in participants who have failed standard treatment.

Read the detailed description

This is a Phase 1b/2, randomized, open label, multicenter, platform study evaluating the safety and efficacy of multiple novel investigational products (IPs) that target mechanisms implicated in resistance to immunotherapy in participants with unresectable or metastatic cutaneous melanoma who have resistance to anti-PD-1/L1 agents. This study will include multiple treatment arms that can be added sequentially or in parallel.

Each arm consists of a selection and expansion part. The selection part is used for evaluation of safety and preliminary efficacy in each arm. The selection part may also include a safety run-in portion for preliminary safety evaluation and dose confirmation prior to proceeding. If the criteria for safety and preliminary efficacy are met, the arm will open for additional enrollment in an expansion phase.

03

Conditions studied

  • Unresectable Cutaneous Melanoma
  • Metastatic Cutaneous Melanoma

Keywords

  • Neoplasms
  • Melanoma
  • Malignant Melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults, age 18 years or older
  2. confirmed unresectable or cutaneous melanoma
  3. Documented radiological progression on prior treatment(s) that included an /L1 agent
  4. Available tumor tissue OR be willing to provide a fresh tumor
  5. Presence of at least one as assessed by CT and/or MRI according to 1.1
  6. Performance Status (ECOG PS) of 0-1
  7. Adequate organ and bone marrow function

Exclusion criteria

Exclusion Criteria:

  1. Known to monoclonal antibodies, any of the IPs, or contained in these products
  2. Current anti-cancer therapy, other treatment, or any participation in other interventional trials
  3. Prior exposure to any therapy that targets the same target as the product under investigation, except for /L1
  4. Known symptomatic/active untreated central nervous system (CNS)
  5. Inadequate recovery from toxicity and/or complications attributable to any previous anti-cancer therapy
  6. Inadequate recovery from all recent surgeries
  7. At least 1-week from the time of minor surgery and at least 4 weeks from a major surgery
  8. Received a within 30 days prior to randomization (or planned to receive a live attenuated vaccine during the study)
  9. History of infection (positive HIV test, not on antiretroviral therapy, detectable viral load)
  10. Active (positive hepatitis B surface antigen test) or infection (positive hepatitis C antibody)
  11. Documented history or current diagnosis of cardiac disease
  12. History of or present CNS disease unrelated to cancer, unless adequately treated with standard medical therapy
  13. Received solid organ or bone marrow transplantation
  14. History of non-infectious pneumonitis requiring therapy within 1 year prior to enrollment, or current presence of interstitial lung disease
  15. Active or previously documented disease including but not limited to inflammatory bowel disease, diverticulitis, celiac disease, systemic lupus erythematosus, Wegener syndrome, multiple sclerosis, and vasculitis
  16. Requiring long term systemic corticosteroids, except topical cortical steroids for intranasal inhalation or physiological dose
  17. Active gastrointestinal (GI) bleeding or GI perforation or fistula
  18. Serious active infection requiring intravenous (IV) antibiotics and/or hospitalization at study entry
  19. Pregnant or lactating women or women who intend to get pregnant or lactate during the study and up to 120 days after the end of treatment
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Treatment Arm 1

    Sintilimab is a recombinant fully human anti-programmed cell death protein 1 (PD-1) monoclonal antibody, and IBI110 is a recombinant fully human anti-lymphocyte activation gene 3 (LAG3) monoclonal antibody. Sintilimab (IBI308) will be administered intravenously (IV) in combination with IBI110 administered intravenously (IV) every 3-weeks (Q3W).

    Combination Product: Sintilimab + IBI110

Interventions

  • Combination productSintilimab + IBI110

    Drug pages: Sintilimab · Negalstobart

    IBI110 infusion in combination with Sintilimab (IBI308) infusion will be given on a Q3W schedule

    Also known as: Sintilimab (IBI308)

06

What researchers measure

Primary outcomes

  1. To evaluate the safety, tolerability, and preliminary efficacy of novel immunotherapy IPs in participants with unresectable or metastatic melanoma that progressed while on prior treatment that included an anti-PD-1/L1 agent. (Selection Part)

    Incidence and severity of Adverse Events (AEs) and laboratory abnormalities

    Time frame: Up to 28 months

  2. To evaluate the safety, tolerability, and preliminary efficacy of novel immunotherapy IPs in participants with unresectable or metastatic melanoma that progressed while on prior treatment that included an anti-PD-1/L1 agent. (Selection Part)

    Incidence of dose-limiting toxicities (DLTs) \[only applicable for safety run-in portion\]

    Time frame: Day 1 to Day 42

  3. To identify novel immunotherapy IPs to progress into the expansion part (Selection Part)

    Overall response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

    Time frame: Up to 2 years

  4. To evaluate the antitumor efficacy of immunotherapy in partcipants with unresectable or metastatic melanoma that progressed while on prior treatment(s) that included an anti-PD-1/L1 agent. (Expansion Part)

    ORR by RECIST 1.1

    Time frame: Up to 2 years

Secondary outcomes

  1. To evaluate the preliminary anti-tumor efficacy by assessing additional endpoints of novel immunotherapy IPs (Selection Part)

    Duration of response (DOR) by RECIST 1.1

    Time frame: Up to 4 years

  2. To evaluate the preliminary anti-tumor efficacy by assessing additional endpoints of novel immunotherapy IPs (Selection Part)

    Time to Response (TTR) by RECIST 1.1

    Time frame: Up to 2 years

  3. To evaluate the preliminary anti-tumor efficacy by assessing additional endpoints of novel immunotherapy IPs (Selection Part)

    Disease control rate (DCR) by RECIST 1.1

    Time frame: Up to 2 years

  4. To evaluate the preliminary anti-tumor efficacy by assessing additional endpoints of novel immunotherapy IPs (Selection Part)

    Progression-free survival (PFS) by RECIST 1.1

    Time frame: Up to 4 years

  5. To evaluate the preliminary anti-tumor efficacy by assessing additional endpoints of novel immunotherapy IPs (Selection Part)

    Overall survival (OS)

    Time frame: Up to 4 years

  6. To characterize the pharmacokinetic (PK) profile and immunogenicity (Selection, Expansion Part)

    Pharmacokinetic parameters including, but not limited to area under the concentration -time curve over dosing interval (AUCtau), Maximum observed plasma concentration at steady state (Cmax,ss), and trough plasma concentration at steady state (Ctrough,ss)

    Time frame: Up to 25 months

  7. To characterize the pharmacokinetic (PK) profile and immunogenicity (Selection, Expansion Part)

    Prevalence and incidence of anti-product antibodies (ADA, Nab)

    Time frame: Up to 25 months

  8. To evaluate anti-tumor efficacy by assessing additional endpoints by RECIST 1.1 (Expansion Part)

    Duration of response (DOR) by RECIST 1.1

    Time frame: Up to 4 years

  9. To evaluate anti-tumor efficacy by assessing additional endpoints by RECIST 1.1 (Expansion Part)

    Time to Response (TTR) by RECIST 1.1

    Time frame: Up to 2 years

  10. To evaluate anti-tumor efficacy by assessing additional endpoints by RECIST 1.1 (Expansion Part)

    Disease control rate (DCR) by RECIST 1.1

    Time frame: Up to 2 years

  11. To evaluate anti-tumor efficacy by assessing additional endpoints by RECIST 1.1 (Expansion Part)

    Progression-free survival (PFS) by RECIST 1.1

    Time frame: Up to 4 years

  12. To evaluate anti-tumor efficacy by assessing additional endpoints by RECIST 1.1 (Expansion Part)

    Overall survival (OS)

    Time frame: Up to 4 years

  13. To further evaluate the safety and tolerability of novel immunotherapy IPs (Expansion Part)

    Incidence and severity of AEs and laboratory abnormalities

    Time frame: Up to 28 months

07

Study locations

13 sites
  • University of California San Francisco Medical Center
    San Francisco, California 94143, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Princess Victoria Hospital
    Woolloongabba, Queensland 4102, Australia
  • Hospices Civil De Lyon Nord - Centre Hospitalier Lyon Sud - Dermatologie
    Lyon, 69002, France
  • Hospital Saint Louis
    Paris, 75010, France
  • Universitatsklinikum Carl Gustav Carus
    Dresden, 01307, Germany
  • Universitatsklinikum Essen
    Essen, 45147, Germany
  • Institut Catala d'Oncologia Hospital Universitari Germans Trials I Pujol, Barcelona
    Barcelona, 8916, Spain
  • Hospital Universitario Reina Sofia, Cordoba
    Córdoba, 14004, Spain
  • Universitaets Spital Zurich
    Zürich, 8091, Switzerland
  • Cambridge University Hospitals NHS Foundation Trust (Oxford)
    Cambridge, CB2 0QQ, United Kingdom
  • Lancashire Teaching Hospitals (Preston)
    Preston, PR2 9HT, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2022; primary completion for Jun 2027, 55 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2022
First posted
Oct 7, 2022
StartEst.
Nov 1, 2022
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05572463
Collaborators
Innovent Biologics (USA), Inc.
Responsible party
Sponsor
First posted
Oct 7, 2022
Start date
Nov 1, 2022 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 18, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sintilimab · Negalstobart

Start the discussion